Mundipharma

What Mundipharma does

Mundipharma is a privately held, Cambridge, UK-headquartered pharmaceutical group that operates as a federation of independently associated national companies across more than 40 countries, employing between 1,001 and 5,000 people globally. The group develops, manufactures, and commercialises prescription medicines across four core therapeutic areas: pain management (anchored by the OxyContin, OxyNorm, MST Continus, and Targin franchises), respiratory disease (Flutiform and related inhaled combination products), oncology, and infectious diseases (notably REZZAYO/rezafungin for candidemia and invasive candidiasis).

The company's revenue model is built on branded specialty pharmaceuticals sold through prescriber, hospital, and retail pharmacy channels, supplemented by geographic licensing and partnership arrangements — most recently a 2026 US commercialisation agreement with CorMedix for REZZAYO. Its underlying technology base is predominantly small-molecule formulation and inhalation-device engineering, extended through the 2018 acquisition of Cinfa Biotech into biosimilars. Late-stage R&D is concentrated on REZZAYO, with Phase III ReSPECT data reported in April 2026 and FDA/EMA submissions planned for 2H 2026 and Q3 2026 respectively, targeting a US market opportunity described as greater than $2 billion.

Operationally, Mundipharma has been actively reshaping its portfolio: it divested its Consumer Health business to iNova Pharmaceuticals in January 2024 to focus on prescription specialty franchises, and continues to operate within a governance framework that includes board-level ESG oversight and a published Modern Slavery Statement. The group's historical association with the Sackler family remains a defining reputational context given the OxyContin franchise.

Name

Mundipharma

Legal name

Mundipharma International Limited

Website

https://mundipharma.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Specialty Pharmaceutical Distributors (HLAIAJAB), Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

Keywords

• Prescription pharmaceuticals
• Pain management therapeutics
• Antifungal medications
• Respiratory treatments
• Oncology supportive care

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices33 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Prescription Pharmaceutical Products: Mundipharma generates revenue through the development, manufacture, and sale of prescription pharmaceutical products across therapeutic areas including pain management, respiratory, oncology, and infectious diseases. The company operates through a global network of independent associated companies.
2. DefenCath: CorMedix reported record 2025 net sales of approximately $260 million driven by DefenCath's TDAPA reimbursement. CorMedix is Mundipharma's US licensee for REZZAYO.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.

Product overview

Mundipharma is a global pharmaceutical company with a diversified portfolio of prescription medicines and consumer health products. The company operates as a network of independent associated companies and focuses on specialty healthcare solutions. Their therapeutic areas include pain management (opioid analgesics such as OxyContin, OxyNorm, MST Continus, Zytram, Targin), respiratory treatments (Flutiform for inhalation), oncology (Zevalin, Pelmeg), and infectious diseases (REZZAYO antifungal). The portfolio comprises both proprietary developed products and licensed brands, with products available across multiple international markets through their global office network spanning over 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• REZZAYO: Antifungal medication (rezafungin) for invasive fungal infections
• Mundipharma Pride

Products and services

• REZZAYO (rezafungin) Antifungal medication for the prophylaxis and treatment of invasive fungal diseases, including for patients undergoing allogeneic hematopoietic stem cell transplantation. Co-developed with CorMedix.
• Flutiform (fluticasone propionate/formoterol fumarate) Pressurized metered-dose inhaler for the management of asthma and COPD, available in 50/5µg, 125/5µg, and 250/10µg dosage strengths. Licensed from Jagotec AG.
• MST Continus (morphine sulfate) Prolonged-release morphine sulfate tablets for pain management, available in 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, and 200mg dosages.
• OxyContin (oxycodone hydrochloride) Prolonged-release oxycodone tablets for chronic pain management, available in 5mg, 10mg, 20mg, 40mg, and 80mg dosages.
• OxyNorm (oxycodone hydrochloride) Injectable oxycodone solution and infusion for acute pain management, available as 10mg/ml solution in 1ml and 2ml ampoules.
• Zytram (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 150mg, 200mg, 300mg, and 400mg dosages.
• Zytram BID (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 75mg twice-daily dosage.
• TARGIN (oxycodone/naloxone) Combination prolonged-release oxycodone/naloxone tablets used in pain management.
• BUTRANS (buprenorphine transdermal) Registered transdermal pain management product of the Mundipharma network.
• ZEVALIN Registered oncology product in the Mundipharma network used in cancer treatment.
• PELMEG (pegfilgrastim) Registered oncology supportive-care biosimilar in the Mundipharma network.

Quantifiable outcome

• 60.7% fungal-free survival at Day 90 for REZZAYO versus 59.0% for standard regimen in Phase III ReSPECT trial
• +1 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• CorMedix TherapeuticscoreStrategic or Co-development Partner · 27 April 2026Mundipharma and CorMedix partnered on the development and commercialization of REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases. The Phase III ReSPECT trial met its primary endpoint demonstrating non-inferiority with 60.7% fungal-free survival at Day 90. The companies plan to submit for FDA approval in 2H26 and EMA approval in Q3 2026. The US market opportunity is estimated to exceed $2 billion.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mallinckrodt: Specialty pharmaceutical company with branded specialty franchises including pain management. Operates across multiple therapeutic areas with a similar specialty-pharma profile to Mundipharma, including legacy opioid exposure.
• Purdue Pharma: Pharmaceutical company historically anchored by OxyContin and other opioid analgesics, sharing therapeutic focus and brand portfolio overlap with Mundipharma's pain franchise. Closely comparable on opioid product positioning.
• Grünenthal: Privately-held German specialty pharmaceutical company with a strong pain management franchise (including branded opioid and non-opioid analgesics) and global commercial operations. Highly comparable to Mundipharma in therapeutic focus and privately-held, specialty-pain-led business model.
• Endo International: Specialty pharmaceutical company with significant pain management portfolio (including opioid analgesics) and branded specialty franchises. Comparable to Mundipharma across pain management focus and specialty pharma positioning, though Endo has faced opioid-related litigation.

Emerging players

• Cidara Therapeutics: Clinical-stage biotechnology company developing antifungal therapies including rezafungin-related programs. Directly comparable to REZZAYO's therapeutic area and competitive positioning in the antifungal space.

Regional players

• Hikma Pharmaceuticals: Specialty pharmaceutical company with strong presence in Middle East, North Africa, and other regional markets, plus specialty injectable and branded portfolio. Comparable to Mundipharma on specialty pharma positioning with regional market overlap.

Broad incumbents

• Stada Arzneimittel: European-headquartered specialty pharmaceutical company with consumer health and specialty care portfolio across multiple therapeutic areas. Comparable as a European specialty pharma peer with similar multi-country distribution model.
• Viatris: Global pharmaceutical company with broad specialty and generics portfolio across multiple therapeutic areas. Comparable to Mundipharma's diversified specialty/generic-style positioning across pain, respiratory, and other areas.
• Astellas Pharma: Global pharmaceutical company with established antifungal franchise and specialty care portfolio. Comparable as a broader incumbent in antifungal/anti-infective therapeutics where REZZAYO competes, and a meaningful peer in specialty pharma.
• GSK (GlaxoSmithKline): Global pharmaceutical major with established respiratory franchise (including inhaler products competing with Flutiform) and broad specialty portfolio. Comparable as a broad incumbent in respiratory therapeutics where Mundipharma operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mundipharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mundipharma